Correlation between extent of myocardial fibrosis assessed by cardiac magnetic resonance and cardiac troponin T release in patients with nonischemic heart failure.
暂无分享,去创建一个
Y. Yamashita | O. Yasuda | Y. Izumiya | S. Hokimoto | S. Takashio | S. Tayama | E. Yamamoto | K. Kaikita | K. Tsujita | H. Ogawa | K. Morita | D. Utsunomiya | M. Yamamuro | S. Sugiyama | S. Kojima | Tomoko Tanaka | Tomoaki Uemura | Yasuhiro Izumiya
[1] T. Sugiura,et al. Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy. , 2013, Journal of the American College of Cardiology.
[2] Y. Izumiya,et al. Coronary microvascular dysfunction and diastolic load correlate with cardiac troponin T release measured by a highly sensitive assay in patients with nonischemic heart failure. , 2013, Journal of the American College of Cardiology.
[3] Tevfik F Ismail,et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. , 2013, JAMA.
[4] D. J. Veldhuisen,et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure , 2013, Clinical Research in Cardiology.
[5] G. Aquaro,et al. Progression of Myocardial Fibrosis Assessed With Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy , 2012 .
[6] J. Gottdiener,et al. Cardiac Microinjury Measured by Troponin T Predicts Collagen Metabolism in Adults Aged ≥65 Years With Heart Failure , 2012, Circulation. Heart failure.
[7] L. Tavazzi,et al. Serial Measurement of Cardiac Troponin T Using a Highly Sensitive Assay in Patients With Chronic Heart Failure: Data From 2 Large Randomized Clinical Trials , 2012, Circulation.
[8] A. Jaffe,et al. Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T. , 2011, Journal of the American College of Cardiology.
[9] M. Horie,et al. Prognostic role of high-sensitivity cardiac troponin T in patients with nonischemic dilated cardiomyopathy. , 2011, Circulation journal : official journal of the Japanese Circulation Society.
[10] Vivek Muthurangu,et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. , 2011, JACC. Cardiovascular imaging.
[11] Y. Pinto,et al. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. , 2011, Cardiovascular research.
[12] Christopher M O'Connor,et al. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. , 2010, Journal of the American College of Cardiology.
[13] Udo Sechtem,et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. , 2010, Journal of the American College of Cardiology.
[14] Arantxa González,et al. Circulating Biomarkers of Collagen Metabolism in Cardiac Diseases , 2010, Circulation.
[15] Alessandro Pingitore,et al. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy , 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[16] S. Heymans,et al. Replacement and reactive myocardial fibrosis in idiopathic dilated cardiomyopathy: comparison of magnetic resonance imaging with right ventricular biopsy , 2010, European journal of heart failure.
[17] A. Jaffe,et al. Analytical validation of a high-sensitivity cardiac troponin T assay. , 2010, Clinical chemistry.
[18] M. Pfeffer,et al. A sensitive cardiac troponin T assay in stable coronary artery disease. , 2009, The New England journal of medicine.
[19] M. Horie,et al. Relationship between renal function and serum cardiac troponin T in patients with chronic heart failure , 2009, European journal of heart failure.
[20] Michael Böhm,et al. Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.
[21] Katherine C. Wu,et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. , 2008, Journal of the American College of Cardiology.
[22] A. Maisel,et al. Natriuretic peptides. , 2007, Journal of the American College of Cardiology.
[23] S. Chugh,et al. Gadolinium-enhanced magnetic resonance imaging for detection and quantification of fibrosis in human myocardium in vitro , 2007, The International Journal of Cardiovascular Imaging.
[24] J. Ornato,et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .
[25] Douglas L Mann,et al. Mechanisms and models in heart failure: the biomechanical model and beyond. , 2005, Circulation.
[26] F. Alla,et al. Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.
[27] M. Fishbein,et al. Characteristics of wave fronts during ventricular fibrillation in human hearts with dilated cardiomyopathy: role of increased fibrosis in the generation of reentry. , 1998, Journal of the American College of Cardiology.
[28] K. Weber,et al. Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.
[29] L. A. Bonet,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[30] K. Weber,et al. Cellular and molecular pathways to myocardial necrosis and replacement fibrosis , 2010, Heart Failure Reviews.
[31] Stefano Geuna,et al. Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. , 2008, Endocrinology.